Compare GHI & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
| Metric | GHI | PGEN |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.5M | 1.5B |
| IPO Year | N/A | N/A |
| Metric | GHI | PGEN |
|---|---|---|
| Price | $7.15 | $4.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $13.00 | $7.67 |
| AVG Volume (30 Days) | 202.0K | ★ 5.1M |
| Earning Date | 02-19-2026 | 11-13-2025 |
| Dividend Yield | ★ 21.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $26,247,399.00 | $6,309,000.00 |
| Revenue This Year | $201.02 | $342.78 |
| Revenue Next Year | $2.87 | $478.46 |
| P/E Ratio | $40.84 | ★ N/A |
| Revenue Growth | N/A | ★ 59.20 |
| 52 Week Low | $6.01 | $0.90 |
| 52 Week High | $13.29 | $5.23 |
| Indicator | GHI | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 55.61 |
| Support Level | $6.52 | $4.05 |
| Resistance Level | $7.35 | $4.53 |
| Average True Range (ATR) | 0.37 | 0.29 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 69.74 | 72.17 |
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.